Drug Trial Radar · NCT05007106
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
611
Actual
Start
Sep 16, 2021
Primary completion
Aug 5, 2025
Study completion Aug 5, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Aug 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
Conditions
- Uterine Cervical Neoplasms
- Endometrial Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Gallbladder Neoplasms
- Cholangiocarcinoma
- Esophageal Neoplasms
- Triple Negative Breast Neoplasms
- Hepatocellular Carcinoma
- Urinary Bladder Neoplasms
- Ovarian Neoplasms
- Stomach Neoplasms
Interventions
Pembrolizumab/Vibostolimab Co-FormulationBiological
Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
PembrolizumabBiological
Pembrolizumab 200 mg administered via IV infusion Q3W.
LenvatinibDrug
Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD
5-FluorouracilDrug
5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles
CisplatinDrug
Cisplatin administered via IV infusion
PaclitaxelDrug
Paclitaxel administered via IV infusion at investigator's choice of dose
GemcitabineDrug
Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity
CarboplatinDrug
Carboplatin administered via IV infusion at investigator's choice of dose and frequency
DocetaxelDrug
For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles
BevacizumabDrug
Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles
CapecitabineDrug
Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles
OxaliplatinDrug
Oxaliplatin administered via IV infusion Q3W up to 35 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1Time frame: Up to approximately 24 months
- Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1Time frame: Up to approximately 24 months
- ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid TumorsTime frame: Up to approximately 24 months
- Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 MonthsTime frame: 9 months
- PFS Per RECIST 1.1 as Assessed by Investigator at 12 MonthsTime frame: 12 months
Locations
73 sites in 15 countries. Site status is shown where the registry gives one.
Alaska Womens Cancer Care ( Site 1016)
Anchorage, Alaska
City of Hope Comprehensive Cancer Center ( Site 1001)
Duarte, California
University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente
Orange, California
Karmanos Cancer Institute ( Site 1007)
Detroit, Michigan
Memorial Sloan Kettering - Basking Ridge ( Site 1023)
Basking Ridge, New Jersey
Memorial Sloan Kettering - Monmouth ( Site 1022)
Middletown, New Jersey
Memorial Sloan Kettering - Bergen ( Site 1025)
Montvale, New Jersey
Memorial Sloan Kettering- Commack ( Site 1021)
Commack, New York
Memorial Sloan Kettering - Westchester ( Site 1020)
Harrison, New York
Memorial Sloan Kettering Cancer Center ( Site 1002)
New York, New York
Memorial Sloan Kettering - Nassau ( Site 1026)
Uniondale, New York
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024)
Tulsa, Oklahoma
Sanford Cancer Center-Gynecologic Oncology ( Site 1015)
Sioux Falls, South Dakota
Houston Methodist Hospital ( Site 1017)
Houston, Texas
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051)
Kingston, Ontario, Canada
Princess Margaret Cancer Centre ( Site 1056)
Toronto, Ontario, Canada
James Lind Centro de Investigacion del Cancer ( Site 1404)
Temuco, Araucania, Chile
FALP-UIDO ( Site 1401)
Santiago, Region M. de Santiago, Chile
Oncovida ( Site 1405)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 1402)
Santiago, Region M. de Santiago, Chile
Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422)
Medellín, Antioquia, Colombia
Clinica de la Costa S.A.S. ( Site 1421)
Barranquilla, Atlántico, Colombia
Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425)
Bogotá, Cundinamarca, Colombia
Oncologos del Occidente ( Site 1424)
Pereira, Risaralda Department, Colombia
Fundación Cardiovascular de Colombia ( Site 1423)
Piedecuesta, Santander Department, Colombia
Institut Curie ( Site 1152)
Paris, France
CENTRE LEON BERARD-Medical oncology ( Site 1151)
Lyon, Auvergne-Rhône-Alpes, France
Centre Georges François Leclerc ( Site 1155)
Dijon, Cote-d Or, France
Institut Regional du Cancer Montpellier ( Site 1157)
Montpellier, Herault, France
Gustave Roussy-medicine departement ( Site 1153)
Villejuif, Paris, France
Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156)
Avignon, Vaucluse, France
Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171)
Berlin, Germany
Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180)
Heidelberg, Baden-Wurttemberg, Germany
Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne
Tübingen, Baden-Wurttemberg, Germany
Klinikum der Universität München Großhadern ( Site 1176)
München, Bavaria, Germany
Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172)
Düsseldorf, North Rhine-Westphalia, Germany
Rambam Health Care Campus-Oncology ( Site 1141)
Haifa, Israel
Hadassah Medical Center-Oncology ( Site 1142)
Jerusalem, Israel
Sheba Medical Center-ONCOLOGY ( Site 1144)
Ramat Gan, Israel
Sourasky Medical Center-Oncology ( Site 1143)
Tel Aviv, Israel
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.